Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model

Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model

Aim: The new formulation of doxorubicin on the base of phospholipid nanoparticles (particle size <30 nm) is elaborated in the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) on the base of plant phospholipids. The aim of study is to investigate an antitumor effect of this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2012
Hauptverfasser: Zykova, M.G., Medvedeva, N.V., Torkhovskava, T.I., Tikhonova, E.G., Prozorovskii, V.N., Zakharova, T.S., Ipatova, O.M.
Format: Artikel
Sprache:English
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2012
Schlagworte:
Original contributions
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/139869
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model / M.G. Zykova, N.V. Medvedeva, T.I. Torkhovskaya, E.G. Tikhonova, V.N. Prozorovskii, T.S. Zakharova, O.M. Ipatova // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 323-326. — Бібліогр.: 26 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-139869
record_format dspace
spelling Zykova, M.G.
Medvedeva, N.V.
Torkhovskava, T.I.
Tikhonova, E.G.
Prozorovskii, V.N.
Zakharova, T.S.
Ipatova, O.M.
2018-06-21T12:47:44Z
2018-06-21T12:47:44Z
2012
Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model / M.G. Zykova, N.V. Medvedeva, T.I. Torkhovskaya, E.G. Tikhonova, V.N. Prozorovskii, T.S. Zakharova, O.M. Ipatova // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 323-326. — Бібліогр.: 26 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/139869
Aim: The new formulation of doxorubicin on the base of phospholipid nanoparticles (particle size <30 nm) is elaborated in the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) on the base of plant phospholipids. The aim of study is to investigate an antitumor effect of this nanoformulation in mice with two cancer models with various sensitivity to chemotherapy — lymphoid malignancy P-388 and Lewis lung carcinoma (LLC). Methods: Nanophospholipid (NPh) formulation of doxorubicin was prepared by homogenization of soybean phosphatidylcholine and doxorubicin hydrochloride. The effect of this formulation was studied in experiments with single or threefold drug administration. Percents of tumor growth inhibition in mice under influence of free or NPh doxorubicin forms were compared. Results: Single administration of both free and NPh doxorubicin in mice with P-388 resulted in the same quick severe inhibition of tumor growth (60–90% depending from dose), with further gradual decrease of inhibition degree. However for more resistant tumor, LLC, the obvious advantage of NPh doxorubicin form was shown. The little effect of free doxorubicin began to reveal only after 11 days, but NPh formulation induced significant inhibition of tumor growth (40%) from the first experimental point (6 days after administration). The advantages of NPh doxorubicin was manifested particularly in low drug doses, 2 and 4 mg/kg. In other experiment design in mice with LLC, with threefold weekly drug administration, NPh doxorubicin appeared to be 2.5 times more active than free drug. The reason of the same actions of free and NPh doxorubicin form in P-388 is suggested the high drug sensitivity of this model, that gives quick high drug response for any doxorubicin form. Conclusion: Doxorubicin in phospholipids nanoformulation revealed higher antitumor efficiency as compared with free doxorubicin in mice with LLC carcinoma. The mechanism of such changes is supposed to be caused by increase of doxorubicin availability for cancer cells.
We thank P.A. Gertsen Moscow Scientific Oncology Institute for maintenance of tumor models.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
spellingShingle Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
Zykova, M.G.
Medvedeva, N.V.
Torkhovskava, T.I.
Tikhonova, E.G.
Prozorovskii, V.N.
Zakharova, T.S.
Ipatova, O.M.
Original contributions
title_short Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
title_full Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
title_fullStr Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
title_full_unstemmed Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
title_sort influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model
author Zykova, M.G.
Medvedeva, N.V.
Torkhovskava, T.I.
Tikhonova, E.G.
Prozorovskii, V.N.
Zakharova, T.S.
Ipatova, O.M.
author_facet Zykova, M.G.
Medvedeva, N.V.
Torkhovskava, T.I.
Tikhonova, E.G.
Prozorovskii, V.N.
Zakharova, T.S.
Ipatova, O.M.
topic Original contributions
topic_facet Original contributions
publishDate 2012
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: The new formulation of doxorubicin on the base of phospholipid nanoparticles (particle size <30 nm) is elaborated in the Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) on the base of plant phospholipids. The aim of study is to investigate an antitumor effect of this nanoformulation in mice with two cancer models with various sensitivity to chemotherapy — lymphoid malignancy P-388 and Lewis lung carcinoma (LLC). Methods: Nanophospholipid (NPh) formulation of doxorubicin was prepared by homogenization of soybean phosphatidylcholine and doxorubicin hydrochloride. The effect of this formulation was studied in experiments with single or threefold drug administration. Percents of tumor growth inhibition in mice under influence of free or NPh doxorubicin forms were compared. Results: Single administration of both free and NPh doxorubicin in mice with P-388 resulted in the same quick severe inhibition of tumor growth (60–90% depending from dose), with further gradual decrease of inhibition degree. However for more resistant tumor, LLC, the obvious advantage of NPh doxorubicin form was shown. The little effect of free doxorubicin began to reveal only after 11 days, but NPh formulation induced significant inhibition of tumor growth (40%) from the first experimental point (6 days after administration). The advantages of NPh doxorubicin was manifested particularly in low drug doses, 2 and 4 mg/kg. In other experiment design in mice with LLC, with threefold weekly drug administration, NPh doxorubicin appeared to be 2.5 times more active than free drug. The reason of the same actions of free and NPh doxorubicin form in P-388 is suggested the high drug sensitivity of this model, that gives quick high drug response for any doxorubicin form. Conclusion: Doxorubicin in phospholipids nanoformulation revealed higher antitumor efficiency as compared with free doxorubicin in mice with LLC carcinoma. The mechanism of such changes is supposed to be caused by increase of doxorubicin availability for cancer cells.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/139869
citation_txt Influence of doxorubicin inclusion into phospholipid nanoformulation on its antitumor activity in mice: increased efficiency for resistant tumor model / M.G. Zykova, N.V. Medvedeva, T.I. Torkhovskaya, E.G. Tikhonova, V.N. Prozorovskii, T.S. Zakharova, O.M. Ipatova // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 323-326. — Бібліогр.: 26 назв. — англ.
work_keys_str_mv AT zykovamg influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT medvedevanv influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT torkhovskavati influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT tikhonovaeg influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT prozorovskiivn influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT zakharovats influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
AT ipatovaom influenceofdoxorubicininclusionintophospholipidnanoformulationonitsantitumoractivityinmiceincreasedefficiencyforresistanttumormodel
first_indexed 2025-11-30T13:39:34Z
last_indexed 2025-11-30T13:39:34Z
_version_ 1850857736271560704

Ähnliche Einträge